ARPC1A

Summary

ARPC1A (actin related protein 2/3 complex subunit 1A, HGNC:703) is a protein-coding gene on chromosome 7q22.1, encoding Actin-related protein 2/3 complex subunit 1A (Q92747). Probably functions as a component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks.

This gene encodes one of seven subunits of the human Arp2/3 protein complex. This subunit is a member of the SOP2 family of proteins and is most similar to the protein encoded by gene ARPC1B. The similarity between these two proteins suggests that they both may function as p41 subunit of the human Arp2/3 complex that has been implicated in the control of actin polymerization in cells. It is possible that the p41 subunit is involved in assembling and maintaining the structure of the Arp2/3 complex. Multiple versions of the p41 subunit may adapt the functions of the complex to different cell types or developmental stages. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 10552 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 64 total — 1 pathogenic
• MANE Select transcript: NM_006409

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:703
Approved symbol	ARPC1A
Name	actin related protein 2/3 complex subunit 1A
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	SOP2Hs, SOP2L, Arc40
Ensembl gene	ENSG00000241685
Ensembl biotype	protein_coding
OMIM	604220
Entrez	10552

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 13 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000262942, ENST00000432786, ENST00000463009, ENST00000471960, ENST00000477240, ENST00000899458, ENST00000899459, ENST00000899460, ENST00000899461, ENST00000899462, ENST00000899463, ENST00000937327, ENST00000937328, ENST00000960463, ENST00000960464, ENST00000960465, ENST00000960466

RefSeq mRNA: 2 — MANE Select: NM_006409 NM_001190996, NM_006409

CCDS: CCDS5660

Canonical transcript exons

ENST00000262942 — 10 exons

Exon	Start	End
ENSE00001055468	99325898	99326004
ENSE00001947928	99365891	99366262
ENSE00003481841	99344293	99344515
ENSE00003546812	99358340	99358415
ENSE00003551555	99338181	99338285
ENSE00003627403	99353909	99354121
ENSE00003628680	99363543	99363633
ENSE00003632159	99359545	99359738
ENSE00003668403	99348852	99348959
ENSE00003809602	99333325	99333417

Expression profiles

Bgee: expression breadth ubiquitous, 164 present calls, max score 98.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 104.9429 / max 1051.6567, expressed in 1822 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79857	97.8827	1822
79858	3.2608	1534
79856	3.0711	1480
79859	0.7283	522

Top tissues by expression

165 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.74	gold quality
mucosa of transverse colon	UBERON:0004991	98.34	gold quality
esophagus mucosa	UBERON:0002469	98.07	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	98.05	gold quality
Ammon’s horn	UBERON:0001954	98.01	gold quality
hypothalamus	UBERON:0001898	98.00	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.92	gold quality
amygdala	UBERON:0001876	97.61	gold quality
substantia nigra	UBERON:0002038	97.56	gold quality
body of stomach	UBERON:0001161	97.54	gold quality
putamen	UBERON:0001874	97.54	gold quality
nucleus accumbens	UBERON:0001882	97.52	gold quality
temporal lobe	UBERON:0001871	97.40	gold quality
apex of heart	UBERON:0002098	97.37	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.37	gold quality
stromal cell of endometrium	CL:0002255	97.36	gold quality
esophagus	UBERON:0001043	97.36	gold quality
left coronary artery	UBERON:0001626	97.36	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.34	gold quality
islet of Langerhans	UBERON:0000006	97.32	gold quality
right frontal lobe	UBERON:0002810	97.30	gold quality
duodenum	UBERON:0002114	97.29	gold quality
fundus of stomach	UBERON:0001160	97.27	gold quality
heart left ventricle	UBERON:0002084	97.24	gold quality
prefrontal cortex	UBERON:0000451	97.20	gold quality
epithelium of bronchus	UBERON:0002031	97.20	gold quality
right coronary artery	UBERON:0001625	97.18	gold quality
adenohypophysis	UBERON:0002196	97.16	gold quality
caudate nucleus	UBERON:0001873	97.14	gold quality
telencephalon	UBERON:0001893	97.09	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-5	no	2.15
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting ARPC1A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-190A-5P	99.54	71.45	933
HSA-MIR-190B-5P	99.54	71.40	925
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-133A-3P	99.27	71.53	1270
HSA-MIR-133B	99.27	71.53	1270
HSA-MIR-4504	99.10	69.14	1328
HSA-MIR-5587-5P	99.07	68.58	838
HSA-MIR-6074	98.89	69.64	2187
HSA-MIR-606	98.72	67.34	960
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-3138	98.41	67.53	744
HSA-MIR-4277	98.34	67.17	1323
HSA-MIR-3620-3P	97.78	64.88	772
HSA-MIR-1287-5P	96.80	65.30	743

Literature-anchored findings (GeneRIF, showing 3)

• data implicate ARPC1A as a novel target for the 7q21-q22 amplification and a regulator of cell migration and invasion in pancreatic cancer (PMID:19145645)
• Development and validation of hub genes for lymph node metastasis in patients with prostate cancer. (PMID:32130760)
• ARPC1A is regulated by STAT3 to inhibit ferroptosis and promote prostate cancer progression. (PMID:35871131)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	arpc1a	ENSDARG00000008383
mus_musculus	Arpc1a	ENSMUSG00000029621
rattus_norvegicus	Arpc1a	ENSRNOG00000000996
drosophila_melanogaster	Arpc1	FBGN0001961
caenorhabditis_elegans		WBGENE00000201

Paralogs (1): ARPC1B (ENSG00000130429)

Protein

Protein identifiers

Actin-related protein 2/3 complex subunit 1A — Q92747 (reviewed: Q92747)

Alternative names: SOP2-like protein

All UniProt accessions (3): Q92747, E9PF58, V9HVZ6

UniProt curated annotations — full annotation on UniProt →

Function. Probably functions as a component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks.

Subunit / interactions. Probable component of the Arp2/3 complex in which it may replace ARPC1B. In addition to its role in the cytoplasmic cytoskeleton, the Arp2/3 complex also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA.

Subcellular location. Cytoplasm. Cytoskeleton. Nucleus.

Similarity. Belongs to the WD repeat ARPC1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q92747-1	1	yes
Q92747-2	2

RefSeq proteins (2): NP_001177925, NP_006400* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR017383	ARPC1	Family
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily

Pfam: PF00400

UniProt features (12 total): repeat 6, sequence conflict 3, splice variant 2, chain 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6YW7	ELECTRON MICROSCOPY	4.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92747-F1	92.23	0.84

Function

Pathways and Gene Ontology

Reactome pathways

24 pathways

ID	Pathway
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation
R-HSA-3928662	EPHB-mediated forward signaling
R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs
R-HSA-8856828	Clathrin-mediated endocytosis
R-HSA-9664422	FCGR3A-mediated phagocytosis
R-HSA-1266738	Developmental Biology
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-194315	Signaling by Rho GTPases
R-HSA-195258	RHO GTPase Effectors
R-HSA-199991	Membrane Trafficking
R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-2682334	EPH-Ephrin signaling
R-HSA-422475	Axon guidance
R-HSA-5653656	Vesicle-mediated transport
R-HSA-5663205	Infectious disease
R-HSA-9658195	Leishmania infection
R-HSA-9664407	Parasite infection
R-HSA-9664417	Leishmania phagocytosis
R-HSA-9675108	Nervous system development
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3
R-HSA-9824443	Parasitic Infection Pathways

MSigDB gene sets: 203 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, ZHAN_LATE_DIFFERENTIATION_GENES_UP, REACTOME_INNATE_IMMUNE_SYSTEM, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, TAL1ALPHAE47_01, REACTOME_MEMBRANE_TRAFFICKING, MODULE_120, GOBP_ACTIN_FILAMENT_ORGANIZATION, NKX22_01, GOMF_ACTIN_BINDING, GOBP_ARP2_3_COMPLEX_MEDIATED_ACTIN_NUCLEATION, MODULE_18, GOBP_ACTIN_NUCLEATION, KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS, TAL1BETAE47_01

GO Biological Process (2): actin cytoskeleton organization (GO:0030036), Arp2/3 complex-mediated actin nucleation (GO:0034314)

GO Molecular Function (3): actin binding (GO:0003779), actin filament binding (GO:0051015), protein binding (GO:0005515)

GO Cellular Component (11): nucleus (GO:0005634), cytosol (GO:0005829), Arp2/3 protein complex (GO:0005885), actin cytoskeleton (GO:0015629), site of double-strand break (GO:0035861), muscle cell projection membrane (GO:0036195), extracellular exosome (GO:0070062), glutamatergic synapse (GO:0098978), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-15 pathways:

Category	Pathways
Fcgamma receptor (FCGR) dependent phagocytosis	1
EPH-Ephrin signaling	1
RHO GTPase Effectors	1
Membrane Trafficking	1
Leishmania phagocytosis	1
Immune System	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Vesicle-mediated transport	1
Innate Immune System	1
Axon guidance	1
Nervous system development	1
Disease	1
Parasitic Infection Pathways	1
Leishmania infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cytoskeleton organization	1
actin filament-based process	1
actin nucleation	1
cytoskeletal protein binding	1
actin binding	1
protein-containing complex binding	1
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
actin cytoskeleton	1
protein-containing complex	1
cytoskeleton	1
site of DNA damage	1
cell projection membrane	1
muscle cell projection	1
extracellular vesicle	1
synapse	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
cell junction	1

Protein interactions and networks

STRING

1923 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARPC1A	ARPC3	O15145	955
ARPC1A	ACTR2	P61160	950
ARPC1A	ARPC2	O15144	935
ARPC1A	ACTR3	P32391	924
ARPC1A	ARPC5	O15511	894
ARPC1A	ARPC5L	Q9BPX5	865
ARPC1A	ARPC1B	O15143	817
ARPC1A	PFN2	P35080	785
ARPC1A	EXOC7	Q9UPT5	733
ARPC1A	WASL	O00401	697
ARPC1A	SMURF1	Q9HCE7	582
ARPC1A	MAPK1	P28482	546
ARPC1A	NOP14	P78316	494
ARPC1A	ZKSCAN5	Q9Y2L8	492
ARPC1A	WAS	P42768	481

IntAct

126 interactions, top by confidence:

A	B	Type	Score
ARPC4	ARPC1B	psi-mi:“MI:0914”(association)	0.910
ARPC1A	ARPC2	psi-mi:“MI:0914”(association)	0.900
ARPC1A	ARPC2	psi-mi:“MI:0915”(physical association)	0.900
ARPC5	ARPC1B	psi-mi:“MI:0914”(association)	0.890
ACTR3	ARPC1B	psi-mi:“MI:0914”(association)	0.890
ASH2L	KMT2D	psi-mi:“MI:0914”(association)	0.890
ARPC3	ARPC1B	psi-mi:“MI:0914”(association)	0.880
ARPC5L	ARPC1B	psi-mi:“MI:0914”(association)	0.830
ARPC5	ARPC3	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
DBNL	HERC2	psi-mi:“MI:0914”(association)	0.670
ARPC3	ARPC2	psi-mi:“MI:0914”(association)	0.640
CAPZB	CNOT1	psi-mi:“MI:0914”(association)	0.640
NCKIPSD	GEMIN2	psi-mi:“MI:0914”(association)	0.640

BioGRID (192): ARPC1A (Affinity Capture-MS), ARPC1A (Affinity Capture-MS), ARPC2 (Affinity Capture-MS), NCAPG (Affinity Capture-MS), NCAPD2 (Affinity Capture-MS), ARPC5 (Affinity Capture-MS), NCAPH (Affinity Capture-MS), ACTR2 (Affinity Capture-MS), ACTR3B (Affinity Capture-MS), ACTR3 (Affinity Capture-MS), ACTR2 (Co-fractionation), ACTR3 (Co-fractionation), ARPC1A (Co-fractionation), ARPC1A (Co-fractionation), ARPC1A (Co-fractionation)

ESM2 similar proteins: A0A1L8EXB5, A4QNE6, A8WGF4, C1BK83, O35142, O43684, O55029, P35605, P35606, Q17QU5, Q1JP79, Q1JQB2, Q29RH4, Q29RZ9, Q3UGF1, Q4FZW5, Q4R4I8, Q561Y0, Q5I0B4, Q5M7F6, Q5MNZ6, Q5R664, Q5RB58, Q5U4Y8, Q5VQ78, Q6GNF1, Q6NWV3, Q6PA72, Q6TGU2, Q803V5, Q8AVT9, Q8BGF3, Q8IWZ6, Q8K2G4, Q8L828, Q8NEZ3, Q8VE80, Q92747, Q96J01, Q96MX6

Diamond homologs: A0A1L8EXB5, O15143, O80856, O88656, O96622, P38328, P78774, Q1JP79, Q58CQ2, Q6GNU1, Q7ZXD5, Q8AVT9, Q92747, Q99PD4, Q9R0Q6, Q9SJW6, Q9WV32

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ARPC1A	“form complex”	ARP2/3	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 99 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RHO GTPases Activate WASPs and WAVEs	11	44.7×	3e-13
Parasite infection	10	44.4×	1e-12
Leishmania phagocytosis	10	44.4×	1e-12
Fcgamma receptor (FCGR) dependent phagocytosis	10	35.7×	1e-11
EPHB-mediated forward signaling	9	30.6×	5e-10
FCGR3A-mediated phagocytosis	12	28.8×	1e-12
Regulation of actin dynamics for phagocytic cup formation	12	28.3×	1e-12
Leishmania infection	11	23.0×	9e-11

GO biological processes:

GO term	Partners	Fold	FDR
Arp2/3 complex-mediated actin nucleation	8	90.6×	9e-12
epidermal growth factor receptor signaling pathway	6	16.0×	6e-04
neuron projection morphogenesis	5	14.8×	2e-03
cellular response to type II interferon	6	13.4×	7e-04
Ras protein signal transduction	5	11.1×	5e-03
actin cytoskeleton organization	9	7.7×	6e-04
regulation of apoptotic process	8	7.2×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	44
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
147547	GRCh38/hg38 7q21.3-36.3(chr7:97419852-158923762)x3	Pathogenic

SpliceAI

1740 predictions. Top by Δscore:

Variant	Effect	Δscore
7:99326001:CCAG:C	donor_loss	1.0000
7:99326003:AGGT:A	donor_loss	1.0000
7:99326005:GTA:G	donor_loss	1.0000
7:99326006:T:G	donor_loss	1.0000
7:99333319:TTGCA:T	acceptor_loss	1.0000
7:99333320:TGCA:T	acceptor_loss	1.0000
7:99333321:GCA:G	acceptor_loss	1.0000
7:99333322:CAGC:C	acceptor_loss	1.0000
7:99333323:A:AG	acceptor_gain	1.0000
7:99333324:G:GA	acceptor_gain	1.0000
7:99333324:GCT:G	acceptor_gain	1.0000
7:99333324:GCTTT:G	acceptor_gain	1.0000
7:99333413:TACTC:T	donor_gain	1.0000
7:99333414:ACTCG:A	donor_loss	1.0000
7:99333415:CTC:C	donor_gain	1.0000
7:99333415:CTCG:C	donor_loss	1.0000
7:99333416:TC:T	donor_gain	1.0000
7:99333416:TCGT:T	donor_loss	1.0000
7:99333417:CGTAA:C	donor_loss	1.0000
7:99333418:G:GG	donor_gain	1.0000
7:99333418:GTAAG:G	donor_loss	1.0000
7:99333419:T:G	donor_loss	1.0000
7:99333420:AAGTA:A	donor_loss	1.0000
7:99338179:A:AG	acceptor_gain	1.0000
7:99338179:AG:A	acceptor_loss	1.0000
7:99338180:G:GG	acceptor_gain	1.0000
7:99338180:GA:G	acceptor_gain	1.0000
7:99338180:GAGA:G	acceptor_gain	1.0000
7:99338180:GAGAT:G	acceptor_gain	1.0000
7:99338282:ACAG:A	donor_loss	1.0000

AlphaMissense

2473 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:99333396:G:C	A15P	1.000
7:99333399:T:A	W16R	1.000
7:99333399:T:C	W16R	1.000
7:99338187:C:A	A24D	1.000
7:99338192:A:C	S26R	1.000
7:99338194:T:A	S26R	1.000
7:99338194:T:G	S26R	1.000
7:99338240:T:A	W42R	1.000
7:99338240:T:C	W42R	1.000
7:99338259:T:C	L48P	1.000
7:99338267:C:G	H51D	1.000
7:99338269:C:A	H51Q	1.000
7:99338269:C:G	H51Q	1.000
7:99344301:T:A	W60R	1.000
7:99344301:T:C	W60R	1.000
7:99344302:G:C	W60S	1.000
7:99344303:G:C	W60C	1.000
7:99344303:G:T	W60C	1.000
7:99344320:G:C	R66P	1.000
7:99344323:T:A	I67N	1.000
7:99344323:T:G	I67S	1.000
7:99344325:G:T	V68F	1.000
7:99344326:T:A	V68D	1.000
7:99344329:C:T	T69I	1.000
7:99344331:T:C	C70R	1.000
7:99344332:G:A	C70Y	1.000
7:99344333:T:G	C70W	1.000
7:99344334:G:A	G71R	1.000
7:99344334:G:C	G71R	1.000
7:99344334:G:T	G71W	1.000

dbSNP variants (sampled 300 via entrez): RS1000013567 (7:99325481 C>T), RS1000043131 (7:99325722 G>A), RS1000097630 (7:99353762 A>T), RS1000184445 (7:99356981 C>T), RS1000360963 (7:99328375 T>C), RS1000451551 (7:99351323 C>T), RS1000469700 (7:99353255 T>A), RS1000605719 (7:99358293 G>T), RS1000636969 (7:99358634 G>A), RS1000751831 (7:99350983 A>G), RS1000768449 (7:99364978 G>A,T), RS1000890407 (7:99365342 T>C), RS1001044345 (7:99326661 A>G), RS1001106138 (7:99326737 A>G), RS1001140282 (7:99358182 G>A)

Disease associations

OMIM: gene MIM:604220 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001038_8	Dehydroepiandrosterone sulphate levels	2.000000e-16
GCST002882_3	Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor	6.000000e-12
GCST004730_2	Facial emotion recognition (sad faces)	3.000000e-06
GCST006249_21	Serum metabolite levels	4.000000e-11
GCST006249_45	Serum metabolite levels	6.000000e-32
GCST007929_102	Medication use (calcium channel blockers)	5.000000e-08
GCST008757_50	Alcohol consumption	3.000000e-10
GCST90002385_143	High light scatter reticulocyte count	2.000000e-26
GCST90002386_454	High light scatter reticulocyte percentage of red cells	8.000000e-20
GCST90002405_484	Reticulocyte count	9.000000e-28
GCST90002406_251	Reticulocyte fraction of red cells	4.000000e-20

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004730	hormone measurement
EFO:0007007	ticagrelor measurement
EFO:0008329	facial emotion recognition measurement
EFO:0009930	Calcium channel blocker use measurement
EFO:0007986	reticulocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression, affects cotreatment, increases methylation	3
Air Pollutants	affects expression, increases abundance, decreases expression	2
Lead	affects expression, increases expression	2
aristolochic acid I	increases expression	1
2,4,6-tribromophenol	increases expression	1
triphenyl phosphate	affects expression	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	increases secretion, affects cotreatment	1
abrine	decreases expression	1
bisphenol S	increases expression	1
LDN 193189	increases expression, affects cotreatment	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Benzene	increases expression	1
Cisplatin	increases expression	1
Dactinomycin	affects cotreatment, increases secretion	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Ozone	affects expression, increases abundance	1
Selenium	increases expression	1
Tobacco Smoke Pollution	affects expression	1
Tretinoin	increases expression	1
Valproic Acid	increases expression	1
Vitamin E	increases expression	1
Cyclosporine	decreases expression	1
Copper Sulfate	decreases expression	1
tert-Butylhydroperoxide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.